Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maoto + Eppikajutsuto to prevent COVID-19 vaccine adverse reactions
jRCTs031230190Recruiting
- Sponsor
- Clinical Research Initiation-Fund (of Chiba University Hospital)
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Open-label, single-arm trial of Maoto and etsuhijika-jutsuto in adverse reaction to COVID-19 vaccine, sponsored by Clinical Research Initiation-Fund (of Chiba University Hospital). Primary endpoint: Post-vaccination fever on day 1 morning. Started Jun 2023; status: recruiting.
02
Drugs
Maotoetsuhijika-jutsuto
03
Conditions
adverse reaction to COVID-19 vaccine
Beyond the preview
Go deeper on jRCTs031230190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230190.